Menu
Search
|

Menu

Close
X

Spectrum Pharmaceuticals Inc SPPI.OQ (NASDAQ Stock Exchange Global Select Market)

9.57 USD
-0.64 (-6.27%)
As of Mar 22
chart
Previous Close 10.21
Open 10.13
Volume 383,798
3m Avg Volume 460,544
Today’s High 10.17
Today’s Low 9.53
52 Week High 25.26
52 Week Low 6.22
Shares Outstanding (mil) 111.05
Market Capitalization (mil) 1,062.75
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
109
FY17
128
FY16
146
EPS (USD)
FY18
-1.161
FY17
-0.686
FY16
-0.950
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
9.72
8.84
Price to Book (MRQ)
vs sector
3.73
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
0.00
17.66
LT Debt to Equity (MRQ)
vs sector
0.00
13.97
Return on Investment (TTM)
vs sector
-35.19
12.12
Return on Equity (TTM)
vs sector
-37.82
13.24

EXECUTIVE LEADERSHIP

Stuart Krassner
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Joseph Turgeon
President, Chief Executive Officer, Director, Since 2017
Salary: $600,000.00
Bonus: $342,000.00
Kurt Gustafson
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $500,000.00
Bonus: $237,500.00
Thomas Riga
Chief Operating Officer, Chief Commercial Officer, Executive Vice President, Since 2017
Salary: $420,000.00
Bonus: $275,000.00
Keith McGahan
Senior Vice President, Chief Legal Officer and Corporate Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11500 S Eastern Ave Ste 240
HENDERSON   NV   89052-5576

Phone: +1702.8356300

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

SPONSORED STORIES